Table 1.

Demographic and clinical characteristics of study patients

	Pre-LTx patients*	Post-LTx
Number of patients	45	49
Age [Median ± SD (range)]	58 ± 9 (35–69)	57 ± 11.5 (21–69)
Gender (Male : Female)	32 : 13	35 : 14
Race (% Caucasian)	93%	92%
Diagnosis
Alcoholic cirrhosis/hepatitis	15	6
NASH	6	5
Viral hepatitis	2	5
PSC/PBC	3	2
HCC#	11	25
Other##	8	6
Immunosuppressive Therapy
Tac + MMF + P		32
Tac + MMF		6
Tac + Evr		1
Tac + P		4
Tac		2
CsA + MMF + P		3
CsA + Az + P		1
Time from LTx
≤ 1month (30 days)		15
> 1 – 3 months (31–91 days)		17
≥ 3 – 8 months (92–244 days)		14
> 8 months		3

^*One patient provided a pre and post-LTx sample.

^#HCC patients’ second diagnoses (if any): pre-LTX - NASH 5, alcoholic cirrhosis/hepatitis 3, viral hepatitis 1; post-LTx NASH 8, alcoholic cirrhosis/hepatitis 5, viral hepatitis 8, congenital biliary atresia 1

^##Other diagnosis: pre-LTx - cryptogenic 4, and 1 each lipodystrophy plus alpha1 antitrypsin deficiency, nodular regenerative hyperplasia, neuroendocrine tumor, substance abuse; post-LTx - 1 each cryptogenic, autoimmune hepatitis, Wilson’s disease, common variable immunodeficiency, cholangiocarcinoma, Waldenstrom’s macroglobulinemia

Abbr: Pre-LTx: pre liver transplant, post-LTx: post liver transplant, NASH: non-alcoholic steatohepatitis, PSC: primary sclerosing cholangitis; PBC: primary biliary cholangitis, HCC: hepatocellular carcinoma, Tac: tacrolimus, CsA: cyclosporine A, MMF: mycophenolate mofetil; P: prednisone, Az:azathioprine; Evr: everolimus